Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection

Journal of Drug Targeting

Volumn 24, Issue 10, 2016, Pages 943-951

  Kim, Yeu Chun ^a   Lee, Su Hwa ^b   Choi, Won Hyung ^b   Choi, Hyo Jick ^c   Goo, Tae Won ^d   Lee, Ju Hie ^e   Quan, Fu Shi ^b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Dongguk University College of Medicine   (South Korea)

^e Kyung Hee University College of Medicine   (South Korea)

Author keywords

Influenza; microneedle; protection; trivalent vaccine

Indexed keywords

CROSS REACTING ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; LD50; LUNG HOMOGENATE; MICRONEEDLE; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PLASMA CELL; PRIORITY JOURNAL; SEASONAL INFLUENZA; SPLEEN; VIRUS IMMUNITY; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INTRADERMAL DRUG ADMINISTRATION; NEEDLE; ORTHOMYXOVIRUS INFECTION;

ANIMALS; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICE, INBRED BALB C; NEEDLES; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84961635275     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2016.1159213     Document Type: Article

References (40)

1. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945–52.
2. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931–9.
3. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009;459:1122–5.
4. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888–97.
5. Mei L, Song P, Tang Q, et al. Changes in and shortcomings of control strategies, drug stockpiles, and vaccine development during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans. Biosci Trends 2013;7:64–76.
6. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 2009;4:e4773.
7. Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010;84:7760–9.
8. Zhu Q, Zarnitsyn VG, Ye L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA 2009;106:7968–73.
9. Barker JN, Griffiths C, Nickoloff BJ, et al. Keratinocytes as initiators of inflammation. Lancet 1991;337:211–14.
10. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin:alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 2000;18:2753–67.
11. Flacher V, Bouschbacher M, Verronese E, et al. Human langerhans cells express a specific TLR profile and differentially respond to viruses and gram-positive bacteria. J Immunol 2006;177:7959–67.
12. Huang J, Garmise RJ, Crowder TM, et al. A novel dry powder influenza vaccine and intranasal delivery technology:induction of systemic and mucosal immune responses in rats. Vaccine 2004;23:794–801.
13. Gill HS, Kang SM, Quan FS, et al. Cutaneous immunization:an evolving paradigm in influenza vaccines. Exp Opin Drug Deliv 2014;11:615–27.
14. Kim YC, Quan FS, Compans R, et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 2010;142:187–95.
15. Quan FS, Kim YC, Yoo D, et al. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 2009;4:e7152.
16. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008;82:1350–9.
17. Sha Z, Compans RW. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 2000;74:4999–5005.
18. Quan FS, Compans RW, Cho Y, Kang S. Ginseng and salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine 2007;25:272–82.
19. Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201:190–8.
20. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 2011;204:582–91.
21. Inn K, Lee G, Quan F. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol Invest 2014;43:236–54.
22. Quan FS, Kim YC, Compans RW, et al. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010a;147:326–32.
23. Slifka MK, Ahmed R. Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Ann NY Acad Sci 1996;797:166–76.
24. Wang B, Gill HS, He C, et al. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release 2014;178:1–7.
25. Kim M, Lee JW, Choi H, et al. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release 2015;28:208–16.
26. Kim YC, Quan FS, Compans R, et al. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 2010;11:1193–201.
27. Kim YC, Quan FS, Compans RW, et al. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res 2011;28:135–44.
28. Ramshaw IA, Ramsay AJ. The prime-boost strategy:exciting prospects for improved vaccination. Immunol Today 2000;21:163–5.
29. Huber VC, McCullers JA. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 2006;193:677–84.
30. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices:a promising chance for vaccine improvement. Exp Opin Biol Ther 2011;11:415–27.
31. Arnou R, Eavis P, De Juanes Pardo J, et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years:randomized, controlled, phase III trial. Hum Vaccin 2010;6:346–54.
32. Haynes L, Swain SL. Why aging T cells fail:Implications for vaccination. Immunity 2006;24:663–6.
33. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults:a randomized controlled trial. J Infect Dis 2008;198:650–8.
34. Liard C, Munier S, Joulin-Giet A, et al. Intradermal immunization triggers epidermal langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 2012;132:615–25.
35. Liu WM, van der Z, Bernard AM, et al. Aging and impaired immunity to influenza viruses:implications for vaccine development. Hum Vaccin 2011;7:94–8.
36. Koutsonanos DG, Vassilieva EV, Stavropoulou A, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012;2:237.
37. Song J, Kim YC, Barlow PG, et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010;88:244–7.
38. Song JM, Kim YC, Lipatov AS, et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol 2010;17:1381–9.
39. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol 2013;21:350–8.
40. Kim M, Lee Y, Hwang HS, et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine 2014;32:5824–31.